Abstract
The inferential issues associated with biomarker studies are enormously complex. False-positive conclusions are rampant in the literature. It is wonderful to have many potential biomarkers in trying to explain the heterogeneity of cancer and outcomes of its treatment. But a large number of biomarkers give rise to statistical headaches. False-positives proliferate. A useful approach is to reduce many biomarkers into a single dimension, and to then attempt to confirm the prognostic or predictive value of the single-dimensional quantity. This is not a panacea for all statistical and scientific ailments, but it minimizes some of the problems. A related concern is subset analysis. I give a statistical argument that estrogen-receptor status is predictive of the benefits of chemotherapy in node-positive breast cancer.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
